Clinical Report: Effectiveness and Safety of Initial Immunotherapy for mTNBC

Overview

This systematic review and Bayesian network meta-analysis evaluated the efficacy and safety of first-line immunotherapy regimens for metastatic triple-negative breast cancer (mTNBC). The findings indicate that immunotherapy combined with chemotherapy significantly improves overall survival and progression-free survival, particularly in patients with higher PD-L1 expression levels.

Background

Metastatic triple-negative breast cancer (mTNBC) is associated with poor prognosis and high recurrence rates, accounting for a significant burden of breast cancer mortality. Traditional treatment options have primarily relied on chemotherapy, highlighting the need for effective therapies. The introduction of immune checkpoint inhibitors (ICIs) represents a promising advancement in the treatment landscape for mTNBC, particularly for patients with PD-L1 expression.

Data Highlights

Key Findings

• Combination of ICIs with chemotherapy significantly improved OS and PFS compared to chemotherapy alone.
• In patients with PD-L1 expression ≥1%, OS and PFS were significantly enhanced with ICIs combined with chemotherapy.
• Toripalimab combined with chemotherapy showed the greatest OS benefit in the overall population.
• Pembrolizumab demonstrated the best safety profile among the regimens evaluated.
• Subgroup analysis indicated that Toripa-chemo conferred the greatest benefit for patients with PD-L1 ≥1%.
• In patients with PD-L1 <1%, Pembro-chemo showed the best OS benefit.

Clinical Implications

The findings support the use of immunotherapy combined with chemotherapy as a first-line treatment for mTNBC, particularly in patients with higher PD-L1 expression. Clinicians should consider the PD-L1 status when selecting treatment regimens to optimize patient outcomes.

Conclusion

Immunotherapy combined with chemotherapy significantly enhances survival outcomes in mTNBC patients, especially in those with PD-L1 positivity. Toripalimab and Pembrolizumab are promising options for first-line treatment.

Related Resources & Content

1. Author(s)/Org, Source, Year -- Title
2. The ASCO Post, Highlights From the 2021 San Antonio Breast Cancer Symposium Guest Editors
3. The ASCO Post, New Computational Tool May Predict Immunotherapy Outcomes in Patients With Metastatic Breast Cancer
4. Breast Cancer Treatment (PDQ®) - NCI
5. The ASCO Post — Identifying Women With Triple-Negative Breast Cancer Who May Benefit From Pembrolizumab Plus Chemotherapy
6. Pembrolizumab (Keytruda)
7. PD-L1 IHC 22C3 pharmDx
8. Breast Cancer Treatment (PDQ®) - NCI